Autori: Yavrom S
| Naslov | HERIZON: A phase II study of HER-Vaxx (IMU-131), a HER2targeting peptide vaccine plus standard of care chemotherapy in patients with HER2+advanced stomach cancer - Dose-dependent anti-cancer antibodies correlating with improved clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G  Petrovic Z Nagarkar R Chawla T Chong LO Nixon B Yavrom S Ede NJ Wiedermann Ursula
|
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 2, str. S864-S864 |
| Ispravka | Web of Science Članak Elečas Rang časopisa |
     |
| Naslov | HERIZON: A phase 2 study of HER-Vaxx (IMU-131), a HER2t-argeting peptide vaccine plus SOC chemotherapy in patients with HER2+advanced stomach cancer - correlation of the antibody responses and clinical outcome (Meeting Abstract) |
| Autori | Tobias Joshua Kundi Michael Garner-Spitzer E Zielinski Christoph Maglakelidze Marina Andric Zoran G Petrovic Zeljko M Nagarkar R Chawla T Chong LMO Nixon B Yavrom S Ede NJ Wiedermann Ursula
|
| Info | ANNALS OF ONCOLOGY, (2023), vol. 34 br. , Suppl. 1, str. S4-S4 |
| Ispravka | Web of Science Članak Elečas Rang časopisa |
|
|
